- Division of Translational and Clinical Sciences – DTCS
- Oncology 2 - Translational Clinical IRG – OTC
- Study Section:
- OTC Special Emphasis Panel Review – ZRG1 OTC-M 08
Dr. Mehrdad Mohseni is the Scientific Review Officer for CSR‘s Oncology 2 - Translational Clinical IRG and reviews applications for research grants that address topics in a variety of areas of biomedical or clinical research.
After receiving his M.D. in 1998 and practicing as a physician in the area of general internal medicine, Dr. Mohseni had postdoctoral training in the area of apoptosis; gene polymorphism and hematology-oncology at three different clinical centers affiliated with Harvard Medical School in Boston and investigated the role of regulatory T-cells in chronic graft versus host disease.